Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 124 clinical trials
A Phase I Clinical Study Evaluating the Safety, Tolerability,of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined Witht Oripalimab in Patients With Advanced Solid Tumors

This is an open-label phase I study to evaluate the safety, tolerability, and initial efficacy of JS004 injection combined with Toripalimab Injection in patients with advanced solid tumors who have failed standard therapy.

  • 0 views
  • 15 Oct, 2022
  • 2 locations
Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II Study

This study is the first clinical study of Neoadjuvant and Adjuvant treatment of head and neck squamous cell carcinoma with drugs targeting EGFR signaling pathway combined with PD-1 inhibitors, which explores the new combination therapies urgently needed in clinical practice and lays a foundation for subsequent studies, with important scientific …

  • 0 views
  • 23 Oct, 2022
  • 1 location
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma (ORIENT-15)

with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma. After the interim analysis conducted by the iDMC, an open-label assignment of experimental arm

measurable disease
chemotherapy regimen
metastatic esophageal squamous cell carcinoma
fluorouracil
sintilimab
  • 41 views
  • 07 Oct, 2022
  • 42 locations
Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer (NEEDS)

squamous cell carcinoma (SCC) of the esophagus, with the aim to provide generalisable guidance for future clinical practice.

esophagectomy
advanced squamous cell carcinoma
oxaliplatin
cancer
carboplatin
  • 6 views
  • 23 Apr, 2022
  • 9 locations
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (SKYSCRAPER-07)

The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresectable esophageal squamous cell carcinoma (or

concurrent chemoradiation
esophageal cancer
cancer
esophagus cancer
carcinoma
  • 7 views
  • 22 Oct, 2022
  • 166 locations
Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma

The purpose of this study is to determined the best definitive radiotherapy dosage for patients with locally advanced esophageal squamous cell carcinoma.

platelet count
esophageal carcinoma
positron emission tomography/computed tomography
chemotherapy regimen
metastasis
  • 0 views
  • 04 Oct, 2022
  • 3 locations
AdvanTIG-203: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

positivity (TAP) ≥ 10% unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma.

carcinoma
squamous cell carcinoma
measurable disease
monoclonal antibodies
  • 12 views
  • 04 Oct, 2022
  • 74 locations
A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer naïve to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06A.

This is a phase I/II multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of investigational agents with pembrolizumab, plus chemotherapy or lenvatinib, for the treatment of participants with advanced esophageal cancer who have failed 1 prior line of therapy and have not been previously exposed to …

cancer
chemotherapy regimen
mk-3475
pembrolizumab
irinotecan
  • 0 views
  • 25 Oct, 2022
  • 8 locations
  • 4 views
  • 27 Oct, 2022
  • 94 locations
A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)

respect to Overall Survival (OS) and Event-free Survival (EFS) in: participants with esophageal squamous cell carcinoma (ESCC), participants whose tumors express Programmed Death

esophageal carcinoma
ebrt
oxaliplatin
chemotherapy regimen
mk-3475
  • 62 views
  • 21 Oct, 2022
  • 139 locations